Research Article

Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice

Table 1

The clinical parameters of study groups.

CharacteristicsWeekdb/mdb/dbdb/db + MMF

Body weight (g)8
20
27.7 ± 0.25
31.4 ± 0.5
42.9 ± 1.76
51.0 ± 3.2
45.2 ± 0.37
50.1 ± 1.9
Daily food intake (g/day)8
20
3.97 ± 0.01
5.6 ± 0.4
5.82 ± 0.28
7.6 ± 1.2
5.76 ± 0.17
8.8 ± 0.8
Daily water intake (mL/day)205.0 ± 0.313.5 ± 0.615.6 ± 1.6
Urine output (mL/day)200.4 ± 0.22.4 ± 1.47.5 ± 3
Fasting glucose (mg/dL)2095.8 ± 14.4391 ± 40.6434.9 ± 40.7
Kidney/BW (%)201.54 ± 0.041.33 ± 0.171.05 ± 0.02
Liver/BW (%)204.85 ± 0.655.9 ± 0.336.1 ± 0.38
Fat/BW (%)203.2 ± 0.54.9 ± 0.176.3 ± 0.6

MMF: mycophenolate mofetil.
The results are expressed as the mean ± S.E.M.
Significantly different with respect to the db/m mice;  #significantly different with respect to db/db mice.
< 0.05.